,i #aadth ,,congress #b;d ,session ,h4 ,r4 #ebai ,,in ,,the ,,house ,,of ,,representatives ,may #ab1 #bjaf ,ms4 ,herrera ,beutler 7for herself and ,ms4 ,castor of ,florida7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to provide for the establishment of the ,task ,force on ,research ,specific to ,pregnant ,women and ,lactating ,women1 to require an annual report to ,congress on approved new drug applications with information on pregnancy and lactation1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,safe ,medications for ,moms and ,babies ,act of #bjaf4 #b4 ,task ,force on research specific to pregnant women and lactating women 7a7 ,task force 7#a7 ,establishment ,not later than #ij days after the date of enactment of this ,act1 the ,secretary of ,health and ,human ,services 7in this section referred to as the ,secretary7 shall establish a task force1 in accordance with the ,federal ,advisory ,committee ,act 7#e ,u4,s4,c4 ,app471 to be known as the ,task ,force on ,research ,specific to ,pregnant ,women and ,lactating ,women 7in this section referred to as the ,task ,force74 7#b7 ,duties ,the ,task ,force shall provide advice and guidance to the ,secretary regarding ,federal activities related to identifying and addressing gaps in knowledge and research regarding safe and effective therapies for pregnant women and lactating women1 including the development of such therapies and the collaboration on and coordination of such activities4 7#c7 ,membership 7,a7 ,federal members ,the ,federal members of the ,task ,force shall be composed of the following members 7or their designees73 7i7 ,the ,director of the ,centers for ,disease ,control and ,prevention4 7ii7 ,the ,director of the ,national ,institutes of ,health1 the ,director of the ,eunice ,kennedy ,shriver ,national ,institute of ,child ,health and ,human ,development1 and the directors of such other national research institutes as the ,secretary determines appropriate4 7iii7 ,the ,commissioner of ,food and ,drugs4 7iv7 ,the ,director of the ,office on ,women's ,health4 7v7 ,the ,director of the ,national ,vaccine ,program ,office4 7vi7 ,the head of any other research-related agency or department not described in clauses 7i7 through 7v7 that the ,secretary determines appropriate1 which may include the ,department of ,veterans ,affairs and the ,department of ,defense4 7,b7 ,non-,federal members ,the non-,federal members of the ,task ,force shall be composed of the following members3 7i7 ,representatives from relevant medical societies with subject matter expertise on pregnant women1 lactating women1 or children4 7ii7 ,nonprofit organizations with expertise related to the health of women and children4 7iii7 ,relevant industry representatives4 7iv7 ,representatives of patient or consumer advocacy organizations4 7v7 ,other representatives1 as appropriate4 7,c7 ,limitations ,the non-,federal members described in subparagraph 7,b7 shall-- 7i7 compose not more than one-half1 and not less than one-third1 of the total membership of the ,task ,force2 and 7ii7 be appointed by the ,secretary4 7#d7 ,termination 7,a7 ,in general ,subject to subparagraph 7,b71 the ,task ,force shall terminate on the date that is #b years after the date on which the ,task ,force is established under paragraph 7#a74 7,b7 ,extension ,the ,secretary may extend the operation of the ,task ,force for one additional #b-year period following the #b-year period described in subparagraph 7,a71 if the ,secretary determines that the extension is appropriate for carrying out the purpose of this section4 7#e7 ,meetings ,the ,task ,force shall meet not less than #b times each year and shall convene public meetings1 as appropriate1 to fulfill its duties under paragraph 7#b74 7#f7 ,task force report to ,congress ,not later than #ah months after the date on which the ,task ,force is established under paragraph 7#a71 and not later than #cf and #dh months after such date if the ,secretary extends the operation of the ,task ,force pursuant to paragraph 7#d77;,b71 the ,task ,force shall prepare and submit to the ,secretary1 the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate1 and the ,committee on ,energy and ,commerce of the ,house of ,representatives a report on gaps in knowledge and research regarding safe and effective therapies for pregnant women and lactating women4 ,each such report shall1 at a minimum1 include each of the following3 7,a7 ,a plan to identify and address gaps in knowledge and research regarding safe and effective therapies for pregnant women and lactating women1 including the development of such therapies4 7,b7 ,ethical issues surrounding the inclusion of pregnant women and lactating women in clinical research4 7,c7 ,effective communication strategies with health care providers and the public on information relevant to pregnant women and lactating women4 7,d7 ,identification of ,federal activities1 including-- 7i7 the state of research involving pregnant and lactating women2 7ii7 recommendations for the coordination of1 and collaboration on1 research related to pregnant women and lactating women2 7iii7 dissemination of research findings and information relevant to pregnant women and lactating women to providers and the public2 and 7iv7 existing ,federal efforts and programs to improve the scientific understanding of the health impacts of therapies on pregnant women and lactating women and related birth and pediatric outcomes1 including with respect to pharmacokinetics1 pharmacodynamics1 and toxicities4 7,e7 ,recommendations to improve the development of safe and effective therapies for pregnant women and lactating women4 7b7 ,confidentiality ,nothing in this section authorizes the ,secretary to disclose any information that is a trade secret1 or other privileged or confidential information1 described in section #eeb7;b77#d7 of title #e1 ,united ,states ,code1 or section #aije of title #ah1 ,united ,states ,code4 7c7 ,updating protections for pregnant women and lactating women in research 7#a7 ,in general ,not later than #b years after the date of enactment of this ,act1 and not later than #c and #d years after such date if the ,secretary extends the operation of the ,task ,force pursuant to subsection 7a77#d77;,b71 the ,secretary1 taking into consideration any recommendations of the ,task ,force available at such time and in consultation with the heads of relevant agencies of the ,department of ,health and ,human ,services1 shall1 as appropriate1 update regulations and guidance1 as applicable1 regarding the inclusion of pregnant women and lactating women in clinical research4 7#b7 ,criteria for excluding pregnant or lactating women ,in updating any regulations or guidance described in paragraph 7#a71 the ,secretary shall consider any appropriate criteria to be used by institutional review boards and individuals reviewing grant proposals for excluding from participating in human subject research pregnant women or lactating women as a study population requiring additional protections4 #c4 ,annual report from ,,fda on approved new drug applications with information on pregnancy and lactation ,not later than #a year after the date of enactment of this ,act1 and not less than annually for the succeeding #i years1 the ,commissioner of ,food and ,drugs shall submit to the appropriate committees of the ,congress a report on-- 7#a7 the number of new drug applications and supplements to such applications approved or licensed by the ,food and ,drug ,administration under section #eje7;c7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act or section #cea7;a7 of the ,public ,health ,services ,act 7#db ,u4,s4,c4 #bfb7;a77 based on research that included pregnant women or lactating women in trials2 7#b7 the number of new drug applications and supplements to such applications so approved or licensed that included data on the excretion of the drug in breast milk2 7#c7 the number of new drug applications and supplements to such applications so approved or licensed with required postmarket studies in pregnant or breastfeeding women2 and 7#d7 the number of drugs with respect to which a labeling change is made to include new information regarding use in pregnant or breastfeeding women4